Search

Displaying results 2121 - 2130 of 8412 in total
  1. Drug

    Omburtamab

    go.drugbank.com/drugs/DB15635
    Investigational

    CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for us...

  2. Drug

    Protego-PD

    go.drugbank.com/drugs/DB18279
    Experimental

    Protego-PD is a post-delivery placental extract.

    Synonyms: Protego-PD
  3. Drug

    PF-05212377

    go.drugbank.com/drugs/DB16044
    Investigational

    PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms

  4. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

  5. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inh...

  6. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. … [A180478] As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in

  7. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  8. Drug

    Relebactam

    go.drugbank.com/drugs/DB12377
    ApprovedInvestigational

    Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combin...

  9. Drug

    RR001

    go.drugbank.com/drugs/DB17369
    Investigational

    (AD-PC sTRAIL). … RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand

  10. Drug

    Ipecac

    go.drugbank.com/drugs/DB13293
    ApprovedWithdrawn

    [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates